Visacor

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Rosuvastatin calcium 10.4mg equivalent to 10 mg rosuvastatin

Disponible desde:

AstraZeneca Limited

Designación común internacional (DCI):

Rosuvastatin calcium 10.4 mg (= 10 mg rosuvastatin)

Dosis:

10 mg

formulario farmacéutico:

Film coated tablet

Composición:

Active: Rosuvastatin calcium 10.4mg equivalent to 10 mg rosuvastatin Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Pink Iron oxide red as Opadry Pink Lactose monohydrate as Opadry Pink   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Pink Triacetin as Opadry Pink

Unidades en paquete:

Blister pack, Al/Al foil, 7 tablets

clase:

Prescription

tipo de receta:

Prescription

Fabricado por:

IPR Pharmaceuticals Inc

indicaciones terapéuticas:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 7 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

Fecha de autorización:

2009-07-31